Login / Signup

Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2.

Peter L FriedlandSimon Tucker
Published in: The Laryngoscope (2024)
2 Laryngoscope, 134:3947-3952, 2024.
Keyphrases
  • sars cov
  • chronic rhinosinusitis
  • respiratory syndrome coronavirus
  • dual energy
  • open label
  • placebo controlled
  • computed tomography
  • clinical trial
  • randomized controlled trial
  • coronavirus disease